

(DRAFT/UNAPPROVED)

**VIRGINIA BOARD OF PHARMACY
MINUTES OF FULL BOARD MEETING**

Tuesday, June 16, 2026

Department of Health Professions
Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233

CALL TO ORDER: A full board meeting was called to order at 9:05AM.

PRESIDING: **Larry Kocot, JD, Chairman**

MEMBERS PRESENT: **Jay Agarwal, RPh**
Shannon Dowdy, PharmD, Vice Chairman
Kelly Hasty Kale, RPh
Jade Ranger, PharmD
Kristopher Ratliff, DPh
Patricia Richards-Spruill, RPh
Derek Webb, PharmD
Ling Yuan, PharmD

MEMBER ABSENT: **Michelle Hoffer Wilgus, JD**

STAFF PRESENT: **Erin Barrett, JD, DHP Director of Legislative and Regulatory Affairs**
David E. Brown, DC, DHP Director
Mykl Egan, Discipline Case Manager
Sorayah Haden, Executive Assistant
Caroline Juran, RPh, Executive Director
Ryan Logan, RPh, Deputy Executive Director
Tim Reilly, Compliance and Innovative Pilot Program Manager
Brent Saunders, JD, Senior Assistant Attorney General

PHARMACISTS AWARDED
1-HOUR OF LIVE OR REAL-
TIME INTERACTIVE
CONTINUING EDUCATION
FOR ATTENDING MEETING: Stephanie Henry – 0202-206285

QUORUM: With 9 members present, a quorum was established.

APPROVAL OF AGENDA: The following amendments to the agenda were presented as follows:

- Amend the Election of Chair and Vice Chair to state “Tentative Election of Chair and Vice Chair”

MOTION

The agenda was adopted as presented and amended. (motion by Ratliff, seconded by Kale)

APPROVAL OF PREVIOUS BOARD MEETING MINUTES

Amendments were offered to the draft minutes included in the agenda packet. Mr. Kocot and Dr. Webb recommended that the Committee on Bylaws minutes be amended to indicate that consensus was reached on each item. While committee member Ratliff and Kale, who was present at the committee meeting but was not a participant, affirmed this understanding, Dr. Brown noted this as an irregularity based on his recollection.

MOTION:

The Board voted unanimously to approve for posting the minutes for the meetings held between March 11, 2026 and May 27, 2026, as presented and amended as follows:

- **Full Board Meeting, held on March 17, 2026 – Amend second bullet point within the citation pertaining to perpetual inventory to state “Accurately indicate the physical count of Schedule II…” on page 11.**
- **Ad Hoc Committee on Bylaws, held on March 17, 2026 – Amend to read that consensus was reached on each of the items.**
- **Formal Hearing, held on May 27, 2026 - Grammatical errors on pages 22, 24, and 26. (motion by Kale, seconded by Dowdy)**

PUBLIC COMMENT:

Justin Hoefling provided a public comment on behalf of the Alliance for Pharmacy Compounding. Dr. Hoefling acknowledged the board’s role in securing patient health specifically highlighting the recent non-approvals of certain compounding pharmacy renewals. He believes the Board’s non-approvals limits patient access and may cause a medication delay for many. Clarity and formal guidance are requested as he believes it is needed to ensure patient access is preserved without an interruption. Additionally, guidance regarding the process to request an informal conference for further consideration as a result of the non-approval of a compounding registration is requested as well.

Jamie Fisher, Executive Director, provided public comment on behalf of the Virginia Pharmacy Association (VPhA). Ms. Fisher expressed gratitude to the Board’s continued engagement with the workforce and the evolution of the industry as it is reflected in various agenda items specifically highlighting the development of a position on Artificial Intelligence. VPhA welcomes a thoughtful approach while protecting pharmacist oversight. She congratulated the two newly appointed members, Dr. Ranger and Mr. Agarwal.

DHP DIRECTOR’S REPORT:

Dr. Brown provided the DHP Director’s Report consisting of the following updates:

- Reviewed a Freedom of Information Act brochure highlighting requirements for a public meeting and public record and emphasized that government work is not intended to be performed in secrecy.
- Requested that board staff be included on any information sent between board members to ensure FOIA requirements are not violated, e.g., ensuring that information for a public meeting is provided to the public at the same time it is provided to board members.

**NATIONAL COMMUNITY
PHARMACISTS
ASSOCIATION**

Jessica Satterfield, PharmD presented a PowerPoint presentation, via Microsoft Teams, on behalf of the National Community Pharmacists Association. The presentation informed the Board of tools used to record data and analyze its pharmacy desert maps. She stated its an open access tool, just have to log in. Data is updated once a year or every other year. Data is based on pharmacies registered with NCPDP. She stated that pharmacy deserts impact 13% of Virginia.

**LEGISLATIVE/
REGULATORY/GUIDANCE**

**REPORT FROM AD HOC
COMMITTEE MEETING ON
BYLAWS**

Dr. Webb provided an overview of the Ad Hoc Committee Meeting previously held on March 17, 2026. He reviewed the red-lined suggested edits to Guidance Document 110-12 in the agenda packet. There was robust discussion on each section.

It was commented that committee appointments would occur once a year in December and as new members are appointed. Dr. Brown stated that having the chairman serve as the spokesperson encroaches on his authority. Counsel recommended that the board could go into closed session for legal advice. There was discussion regarding the number of members for a special conference committee or pilot committee. It was noted that the Inspection Special Conference Committee should be stricken. It is intended that the delegations in Article V will be placed in a separate document. Dr. Brown suggested periodically reviewing delegations at existing board meetings, in lieu of creating a committee to review. There was discussion regarding placing the bylaws in a policy document in lieu of a guidance document. The chairman was reluctant for staff to enter into closed session with the Board, but counsel advised that Dr. Brown, Ms. Juran, and Ms. Barrett should participate.

CLOSED SESSION

Upon a motion by Dr. Kale to go into closed session, and duly seconded by Dr. Yuan, the Board voted unanimously to convene a closed meeting pursuant to §2.2-3711(A)(8) of the Code of Virginia (“Code”) to consult with counsel regarding the proposed amendments to Guidance Document 110-12, Bylaws of the Virginia Board of Pharmacy. Additionally, she moved that Caroline Juran,

Erin Barrett, and Dr. Brown attend the closed meeting because their presence is deemed necessary and will aid the Board in its deliberations.

RECONVENE

After approximately two hours (1:25pm) and upon the motion by Dr. Dowdy who motioned to go into open session, and duly seconded by Ms. Richards-Spruill, who seconded the motion to go into open session, having certified that the matters discussed in the closed meeting met the requirements of §2.2-3712 of the Code, the Board reconvened an open meeting.

MOTION

The Board voted unanimously to amend Guidance Document 110-12, Bylaws of the Virginia Board of Pharmacy as presented in the agenda packet and further amended as follows:

- **Article I: General**
 - Second paragraph, after “members of the Board” strike “present”;
- **Article II: Officers of the Board**
 - Subsection B, strike the proposed sentences, “The chairman shall act as the chief representative and spokesperson for the Board between meetings and shall perform all functions pertaining to the position of the chairman. The chairman or his/her designee shall act as the representative of the Board to the Department of Health Profession and any other outside organization that requires Board representation.” And replace with “The chairman shall perform all functions pertaining to the position of chairman.”
 - Subsection B, at the end of the sentence, “The chairman may call for additional meetings of the Board pursuant to Article I of these bylaws”, insert “subject to availability of resources.”
 - Subsection E, after “the chairman shall solicit” insert “verbal and confidential” and after “shall be shared” insert “verbally and confidentially” and after “Director of Health Professions” insert “and the Executive Director of the Board.”
- **Article IV: Committees**
 - Subsection A, strike “Inspection Special Conference Committee”;
 - Subsection (A)(1), first sentence, strike “of not less than”;
 - Subsection (A)(3), after “not less than two” insert “but not greater than three”;
- **Article V: Annual General Delegation of Authority**
 - After “organizational year,” insert “or for good cause,”;
- **Article VI: Amendments**
 - Strike the last sentence “Any amendment of these bylaws shall become effective upon passage by the Board and any preexisting Guidance Document that is inconsistent with

any such amendment shall be null and void.” (motion by Kale, seconded by Ratliff)

FORMATION OF AD HOC COMMITTEE ON ROUTINE PHARMACY INSPECTIONS

Mr. Kocot announced that an ad hoc committee on routine pharmacy inspections will be formed and that Ms. Kale will chair the committee. He will name four members soon with the goal of completing the work by the end of the year.

DEVELOPING A BOARD POSITION ON ARTIFICIAL INTELLIGENCE

The Board reviewed the Louisiana Board of Pharmacy’s recent newsletter article which addressed the Board’s position on Artificial Intelligence (AI). The board was pleased with Louisiana’s position as it welcomed the innovation of AI with the appropriate measures and guidelines. The Board would like to draft a similar statement which embraces AI but acknowledges it does not override the human judgement of the pharmacist.

ACTION ITEM:

Board members will submit suggested edits to Louisiana’s position on AI to Ms. Juran and staff will draft a possible guidance document on the subject for consideration at a future meeting.

LEGISLATIVE UPDATE

Ms. Barrett stated that there were no legislative updates to provide.

CHART OF REGULATORY ACTIONS

Ms. Barrett reviewed the Regulatory Chart included in the agenda packet and provided updates on any actions taken since the agenda was posted.

In response to a question from a board member, Dr. Brown informed the Board the agency is currently exploring alternative funding opportunities if the proposed bill regarding fee increases were not to be approved.

ADOPTION OF EXEMPT REGULATORY ACTION – ADDITION OF CHEMICALS TO SCHEDULE I

The Board reviewed and discussed the recommendations from the Virginia Department of Forensic Science to place certain chemicals into Schedule I.

MOTION:

The Board voted unanimously to adopt the recommendation from the Virginia Department of Forensic Science to place the following chemicals into Schedule I:

The following compounds are classified as synthetic opioids. Compounds of this type have been placed in Schedule I (§ 54.1-3446(1)) in previous legislative sessions.

- 1. 3-[2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol (other names: O-desmethyltramadol, ODMT), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.**

2. **3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one (other names: chlorphine; 1-[1-[1-(4-chlorophenyl)ethyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.**
3. **3-[3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]propanenitrile (other names: cycchlorphine; N-propionitrile chlorphine), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.**

Based on their chemical structure, the following compounds are expected to have hallucinogenic properties. Compounds of this type have been placed in Schedule I (§ 54.1-3446(3)) in previous legislative sessions.

4. **[3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-yl] acetate (other names: 4-acetoxy-N-methyl-N-ethyltryptamine, 4-acetoxy-MET, 4-AcO-MET), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.**
5. **1-(4-bromophenyl)-2-pyrrolidin-1-ylpentan-1-one (other names: 4-bromo-alpha-pyrrolidinovalerophenone, 4-bromo-alpha-PVP), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.**
6. **1-[1-(3-methylphenyl)cyclohexyl]piperidine (other names: 3-methyl phencyclidine, 3-methyl PCP), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation. (motion by Webb, seconded by Yuan)**

**ADOPTION OF EXEMPT
REGULATORY ACTION –
CONFORMING TO RECENT
FEDERAL DRUG
SCHEDULING ACTIONS
MOTION:**

The Board reviewed and discussed the compilation of recent federal scheduling actions and the proposed amendments to 18VAC110-20-323.

The Board voted unanimously to adopt the exempt changes to 18VAC110-20-323 to conform Virginia schedules to recent federal scheduling actions as presented. (motion by Dowdy, seconded by Webb)

The Board reviewed and discussed the proposed amendments to 18VAC110-20-322 to remove the chemicals from regulation since they had been added to the Virginia Code by the General Assembly.

ADOPTION OF EXEMPT
REGULATORY ACTION –
REMOVAL OF CHEMICALS
IN SCHEDULE I PURSUANT
TO LEGISLATION

MOTION:

The Board voted unanimously to adopt the exempt changes to 18VAC110-20-322 to remove chemicals from Schedule I which are no longer needed in regulation since they are now in Code. (motion by Kale, seconded by Webb)

The Board reviewed and discussed the draft regulatory amendments to include “animal hospital” in the definition of “hospital” found in 18VAC110-20-10.

AMEND DEFINITION OF
“HOSPITAL” IN 18VAC110-
20-10 TO INCLUDE A
HOSPITAL FOR ANIMALS
WITH A VETERINARY
ESTABLISHMENT PERMIT

MOTION:

The Board voted unanimously to adopt the regulatory changes to 18VAC110-20-10 to amend the definition of “hospital” as presented. (motion by Kale, seconded by Ranger)

The Board reviewed and discussed the draft amendments to Guidance Document 110-19 to include animal hospitals approved by the Board in the Board’s interpretation of “other facilities” that may use an automated dispensing device or remote dispensing system.

AMEND GUIDANCE
DOCUMENT 110-19 TO
INCLUDE LANGUAGE
UNDER INTERPRETATION
OF “OTHER FACILITIES”
THAT MAY USE AN ADD
THAT WILL INCORPORATE
VIRGINIA TECH ANIMAL
HOSPITAL

MOTION:

The Board voted unanimously to adopt the amendments to Guidance Document 110-19 as presented. (motion by Webb, seconded by Agarwal)

The Board reviewed and discussed the draft amendments to 18VAC110-20-710(F) exempting analytical labs from alarm systems.

AMEND CSR REGULATIONS
REGARDING
RESEARCHERS AND
OTHERS

MOTION:

The Board voted unanimously to adopt the fast-track regulatory action to amend 18VAC110-20-710(F) to exempt analytical labs from alarm

systems and replace the term “humane societies” with “animal shelters” as presented. (motion by Ratliff, seconded by Webb)

The Board reviewed and discussed SB418 which directs the Board to promulgate regulations to implement the provisions of the legislation. The Board will work on specific regulatory language while the NOIRA is under Executive Branch review. A regulatory advisory panel will be likely be convened in late August or early fall to help inform the development of the draft regulations.

The Board voted unanimously to adopt a notice of intended regulatory action regarding therapeutic interchange and adaption, including regulation of which therapeutic classes of drugs are eligible for therapeutic interchange and which therapeutic classes will be prohibited as presented. (motion by Yuan, seconded by Dowdy)

The Board reviewed and discussed the redline of proposed changes to Guidance Document 110-44. Ms. Juran recommended correcting the hyperlinks to the resources listed at the end of the document in lieu of striking them.

The Board voted unanimously to amend Guidance Document 110-44 as presented and further amended to replace the broken links under “Resources” with current links. (motion by Kale, seconded by Agarwal)

The Board reviewed and discussed the proposed amendments to Guidance Document 110-2.

The Board voted unanimously to adopt the amendments to Guidance Document 110-2 as presented. (motion by Yuan, seconded by Dowdy)

The Board reviewed the redline of proposed changes to Guidance Document 110-35. Staff noted that the proposed changes clarify that pharmacy technicians may electronically transfer a refill for a Schedule VI drug under certain circumstances.

The Board voted unanimously to adopt the amendments to Guidance Document 110-35 as presented. (motion by Agarwal, seconded by Webb)

ADOPTION OF NOIRA FOR
SB418 – PHARMACIST
THERAPEUTIC
INTERCHANGE OF DRUG

MOTION:

AMENDMENT OF
GUIDANCE DOCUMENT
110-44 NALOXONE OR
OTHER OPIOID
ANTAGONIST PROTOCOLS

MOTION:

AMENDMENT OF
GUIDANCE 110-2
REGARDING
IMPLEMENTATION OF
UMPJE

MOTION:

AMENDMENT OF
GUIDANCE DOCUMENT
110-35 REGARDING
ELECTRONIC TRANSFER OF
PRESCRIPTIONS BY
PHARMACY TECHNICIANS

MOTION:

Old Business

REPORT ON PHARMACIES
PROVIDING CLINICAL
SERVICES

In follow-up to a previous Board action item, Barbara Hodgdon, PhD, Deputy Director, DHP Healthcare Workforce Data Center and Data Analytics Division presented the data collected in response to questions included in the annual pharmacy renewal process which ended on April 30, 2026 regarding whether the pharmacy provided certain clinical services. Staff requested feedback from the Board regarding how they wanted the data to be provided. Dr. Hodgdon provided examples of the available formats, such as dashboards and live maps, the Health Workforce Data Center could use to present the data collected at renewals moving forward. Board members expressed interest in an interactive map as it will be a helpful resource to providers and patients. The Board would like to have the reported data accessible for public use through the Board's website.

ACTION ITEM:

Staff will begin developing a process to display on its website any trends of the aggregate data regarding pharmacies providing clinical services and an interactive map with a drop down to choose a particular clinical service and a means of identifying the individual pharmacies providing such services.

REPORT ON NONRESIDENT
PHARMACY PRACTICE
SETTINGS AND LOCATIONS

In follow-up to a previous Board action item, Ms. Juran provided an overview of a report of the practice types for all currently active nonresident pharmacy registrations as of April 15, 2026. The Board discussed the potential need to collect more in-depth data to appropriately address any concerns of the board regarding nonresident pharmacies. The Board will follow up on the discussion at the next Regulations Committee meeting.

FINALIZE PLANS FOR
TRANSITIONING TO UMPJE

The Board reviewed the draft communication in the agenda packet that staff recommend sending to new pharmacist licensees via email upon issuance of their license encouraging them to review the Virginia-specific information. Staff will revise the list as needed to ensure it remains current.

MOTION:

The Board voted unanimously to require pharmacist applicants to pass the Uniform Multistate Pharmacy Jurisprudence Examination (UMPJE) as of October 1, 2026, in lieu of the Virginia-MPJE and for staff to send new pharmacist licensees a current list of laws and regulations specific to Virginia via email upon issuance of their license, strongly encouraging their review of the information. (motion by Webb, seconded by Agarwal)

New Business

ELECTION OF CHAIR AND
VICE CHAIR

The Chairman called for nominations for chairman and vice chairman. Larry Kocot and Shannon Dowdy were nominated for chairman and vice chairman, respectively. No other nominations were made. The terms of the positions under the current bylaws are from July 1, 2026 until June 30, 2027. Such terms are subject to change once the amendments to the current bylaws, which must go through an Administrative Review process, become effective.

MOTION:

The Board voted unanimously to elect Mr. Kocot as Chairman and Dr. Dowdy as Vice Chairman. (motion by Webb, seconded by Ratliff)

Reports

LICENSURE PROGRAM

Mr. Logan provided an overview of the Licensure Program consisting of licensing data on Individuals and Facility licenses from Q2 2023 through Q3 2026. The overview included the following current license count as of June 1, 2026:

- Pharmacist – 16,700
- Pharmacy Technician – 13,976
- Pharmacy Technician Trainee – 7,233
- Pharmacy Intern – 1,059
- Resident Pharmacies – 1,689
- Nonresident Pharmacies – 1,003

Additionally, Mr. Logan provided a bar graph to document the new pharmacy permits issued compared to pharmacy permits closing. At the request of a board member, the next licensing report will include the practice types of the pharmacy closures and openings.

INSPECTIONS PROGRAM

Mr. Reilly provided an overview of the Inspections Program. The overview consisted of all inspections conducted during the period of January 1, 2026 through March 31, 2026. As of March 31, 2026, the Inspections Program conducted a total of 585 inspections consisting of 541 in-person inspections and 44 virtual inspections. The top 5 cited deficiencies reported are as follows:

- Compounding facilities and equipment used in performing non-sterile compounds not in compliance with 54.1-3410.2 (cited 26 times)
- Expired drugs in working stock, dispensed drugs being returned to stock not in compliance, dispensed drugs returned to stock container or automated counting device not in compliance (i.e. appropriate expiration date not placed on label of returned drug, mixing lot numbers in stock container) (cited 19 times)
- Perpetual inventory not being maintained as required as it does not
 - Include all Schedule II drugs received or dispensed
 - Accurately indicate the physical count of Schedule II drug “on hand” at the time of performing the inventory
 - Include a reconciliation of each Schedule II drug at least monthly
 - Include a written explanation of any difference between the physical count and the theoretical count

Monthly perpetual inventory is performed more than 7 days prior or more than 7 days after designated calendar month for which an inventory is required (cited 14 times)

- No incoming change of Pharmacist-in-Charge inventory, inventory taken over 5 days late, or substantially incomplete i.e. did not include all drugs in Schedules II-V (cited 12 times)
- Labels do not include all required information. (cited 11 times)

The Board requested clarification regarding a previous public comment which mentioned the non-approval of compounding pharmacy permit renewals. Ms. Juran explained the renewal requirements for nonresident compounding pharmacies and their ability to request an informal conference for further consideration.

DISCIPLINARY PROGRAM

Ms. Juran reviewed the Disciplinary Report. The overview consisted of cases received, opened, and closed from Q2 of 2023 through Q3 of 2026. As of Q3 of 2026, ending March 31, 2026, the Board received 211 cases, opened 371 cases, and closed 165 cases. As of May 27, 2026, the Board currently has an open case count of 410 consisting of 240 patient care cases and 170 non-patient care cases.

2027 NABP/AACP DISTRICTS 1 & 2 MEETING

Dr. Webb informed the Board of the following updates regarding the 2027 NABP/AACP District 1 & 2 meeting to be hosted by the Virginia Board of Pharmacy:

- The meeting will be held in October 2027
- A lodging contract has been confirmed with the Williamsburg Lodge.
- More targeted meetings will be forthcoming starting August 2026.

CHAIRMAN'S REPORT

Mr. Kocot thanked the Board for their continued efforts and support. He expressed appreciation by acclamation by the Board for the continued efforts of Ms. Patricia Richards-Spruill, Dr. Ratliff, and Dr. Yuan during their time on the Board.

APhA INSTITUTE ON SUBSTANCE USE DISORDER

Dr. Yuan expressed gratitude for her experiences at the Substance Abuse Disorder Symposium. She explained it was an immersive experience which developed a higher level of appreciation of the Health Practitioners Monitoring Program and the Board's efforts regarding licensees with substance abuse disorders. She encourages all to attend if able.

EXECUTIVE DIRECTOR'S REPORT

Ms. Juran welcomed the new board members and thanked the board members who will be leaving the board soon as their terms end. She provided an update on the meetings that she attended or at which she provided presentations either in-person or virtually since the March board meeting and any upcoming meetings and presentations currently on her schedule. More board member presence at NABP events is desired. She announced the recent passing of a former board member and DHP Director, Bernie Henderson, Jr.

**POSSIBLE SUMMARY
SUSPENSION
PRESENTATION**

Case #251811 – Christina Sanchez, Pharmacy Technician #0230043420
Rebecca Ribley, Adjudication Specialist, presented a possible summary suspension presentation for Board consideration regarding Christina Sanchez (Pharmacy Technician #0230043420).

DECISION

Upon a motion by Ratliff and duly seconded by Dowdy, the Board voted unanimously to summarily suspend the Pharmacy Technician registration and offer a consent order in lieu of a Formal Hearing for Christina Sanchez (Pharmacy Technician #0230-043420).

**AGENCY SUBORDINATE
RECOMMENDATIONS**

Mr. Egan provided information regarding the agency subordinate's recommendations resulting from a recent informal conference. Mr. Agarwal recused himself from voting due to knowledge of a licensee who is a respondent to the agency subordinate's recommendations.

DECISION

Tiffany White, Pharmacy Technician
Upon a motion by Yuan, and duly seconded by Ranger, the Board voted (8-0, Agarwal recused) to accept the agency subordinate recommendation as presented and amended to include clarification regarding the reinstatement process required should the license lapse before the Continue Education credits are obtained for Tiffany White.

DECISION

Raj Narla, Pharmacist
Upon a motion by Webb, and duly seconded by Ranger, the Board voted (7-1 Kale opposed, Agarwal recused) to accept the agency subordinate recommendation as presented for Raj Narla.

MEETING ADJOURNED:

5:04PM

Caroline Juran, RPh
Executive Director

Date